| Deere & Co [DE] - Last Close: $416.56 John Deere is trending after an earnings release. The agricultural equipment company reported fiscal Q4 results this morning that surpassed analysts' expectations. Deere earnings rose 75% to $7.44 per share and beat the Street's $7.11 EPS estimate. Revenues of $15.54 billion also topped the consensus estimate of $13.39 billion. The double-line beat lifted DE to the top of the S&P 500. It's currently leading the large-cap index with a 4.1% gain. My Take: Deere has done surprisingly well over the past few months, but the real test will be if it can break above $450. At its current price point, I think there's a more downside risk than there is upside potential. Venus Concept [VERO] - Last Close: $0.2188 Reports of Insider buying is boosting shares of Venus Concept. CEO Rejiv De Silva executed a purchase for 1.25 million shares of VERO for $250,000, according to a recent Form 4 filing. With the purchase, De Silva officially has "skin in the game." Previously, he didn't hold any shares of the company. However, as of the transaction, he now directly controls 1.25 million shares of VERO, the equivalent of a 1.8% stake in the company. The CEO isn't the only one buying. Several Form 4 filings have revealed major purchases by company insiders in recent days. Shares of VERO are up 14.2% on the rush of insider purchasing activity. My Take: This is an extremely unusual amount of insider buying. It's hard to imagine there isn't something cooking behind the scenes in this stock. A stock this small is always a gamble, but all the insider purchasing is undoubtedly an encouraging sign for the stock. NeuroBo Pharmaceuticals Inc [NRBO] - Last Close: $1.20 NeuroBo Pharma is moving higher on news of Wall Street interest. According to a Form 3 filing dated today, Goldman Sachs has acquired 1.22 million shares of NRBO stock. The Wall Street firm's ownership in the company was just made public via the regulatory filing. The purchase puts Goldman in control of an 18.7% stake in the company. NRBO is up 18.3% on the news. My Take: Goldman just pounced on this tiny pharma stock, but why? They could have big plans for the company, including taking it private or affecting a merger with a larger pharma firm. Shareholders could be in line for a big windfall. Revelation Biosciences [REVBU] - Last Close: $0.28 Revelation Bio undergoing a rebound rally. The tiny biopharma firm touched a new 52-week low of $0.19 per share in Tuesday's trading session, but shares are changing course in today's premarket. Last week, the company outlined its plans for a human trial of its lead fibrosis candidate, REVTx-300. In the announcement, Revelation said it was planning several Phase 1 studies for 1H 2023.
Since then, the newswires have been quiet. No major news for REVBU this week, except for the new 52W low.
Regardless, REVBU is one of today's top performers with a 21.4% gain. My Take: Not sure what is driving this move, but it could be a classic swing trade setup. The stock's sudden rebound from Tuesday's 52W low could be a sign that the stock's recent sell-off was overdone. GainersCosmos Holdings [COSM] >> +32.5%COMSovereign Holdings [COMS] >> +41.7%Golden Sun Education [GSUN] >> +25.6%DeclinersBYND Cannasoft [BCAN] >> (24.1%)Motorsports Gaming [MSGM] >> (14.7%)Autodesk [ADSK] >> (9.3%) Full Truck Alliance Co. Ltd. [YMM] ... AM
Up Fintech Holding Limited [TIGR] ... AM
Aurora Mobile Limited [JG] ... AM
Via Optronics Ag [VIAO] ... AM
Viomi Technology Co., Ltd [VIOT] ... AM
Sunlands Technology Group [STG] ... AM
Lufax Holding Ltd [LU] ... PM | 